CNTF and retinitis pigmentosa 1: Additionally, current treatments under investigation include the same voretigene neparvovec-rzyl that was FDA-approved for LCA treatment, AAV serotype 8 (AAV8)-sCX3CL1, and ciliary neurotrophic factor (CNTF)- secreting neural stem cells (NSC) that have provided potential protection to photoreceptor cells in RP models [17–19].